#ViiV Healthcare

“As Much As I Can” debuted in the South. This week, it opens in Harlem, New York.

Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.

ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).

Who are the top 20 funders across the globe? This annual FCAA report lists them all.

The Southern HIV Impact Fund is a collaborative partnership managed by AIDS United.

The single-tablet regimen contains ViiV’s Tivicay (dolutegravir) and Janssen’s Edurant (rilpivirine).

Early results from an ongoing trial show that 24 weeks after adding the drug to their HIV regimen, half were virally suppressed.

Respondents reported on their feelings about antiretrovirals, their relationships with their clinicians and dealing with stigma.

Called #PWNCares, the multimedia series launches Monday, October 23, from Positive Women’s Network–USA.

AIDS United, NMAC and other HIV leaders can help you help those in dire need. Here’s how.

ViiV Healthcare has applied to the FDA for approval of the first two-drug antiretroviral (ARV) regimen to treat HIV.

ViiV’s Positive Action for Women initiative aims to break down isolation and stigma.

Each receives up to $200,000 thanks to ViiV Healthcare’s Positive Action for Youth program.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.